Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Large Decline in Short Interest

Aspira Women’s Health Inc. (NASDAQ:AWH) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 438,500 shares, a decline of 11.8% from the November 30th total of 497,300 shares. Based on an average trading volume of 93,300 shares, the days-to-cover ratio is presently 4.7 days. Currently, 3.8% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Aspira Women’s Health in a research note on Tuesday. They issued a “hold” rating on the stock.

Aspira Women’s Health Trading Up 1.6 %

NASDAQ:AWH traded up $0.01 during mid-day trading on Tuesday, hitting $0.71. The company’s stock had a trading volume of 46,122 shares, compared to its average volume of 77,111. Aspira Women’s Health has a fifty-two week low of $0.67 and a fifty-two week high of $5.65. The stock has a fifty day moving average of $0.81 and a 200-day moving average of $1.01. The company has a market capitalization of $11.90 million, a price-to-earnings ratio of -0.59 and a beta of 1.39.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new position in Aspira Women’s Health Inc. (NASDAQ:AWH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health at the end of the most recent reporting period. 12.19% of the stock is owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.